BridgeMD
Prevention study for Acute Myocardial Infarction of Anterior Wall
Official title Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction
ClinicalTrials.gov ID: NCT06742567
What this study is testing
What is Apixaban 2.5 MG PO BID?
Apixaban 2.5 MG PO BID is an investigational medicine, given as an once-daily, being studied as a potential treatment for acute myocardial infarction of anterior wall.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Patients aged 18-65 years
- Presenting with acute anterior STEMI
- Severe LV dysfunction (EF\<35%) with antero-apical akinesis, dyskinesis, or aneurysm
- WIHTOUT evidence of LV thrombus.
You likely can't join if
- Patients with previous anterior myocardial infarction or LAD revascularization procedures
- Patients with cardiogenic shock
- Patients with LV thrombus
- Patients with advanced CKD (Cr \> 2 and those on hemodialysis)
- Recent ICH or major bleed requiring transfusion, low platelet counts \<100,000
- History of recent CVA ( within past three months)
See the full eligibility criteria
- Patients aged 18-65 years
- Presenting with acute anterior STEMI
- Severe LV dysfunction (EF\<35%) with antero-apical akinesis, dyskinesis, or aneurysm
- WIHTOUT evidence of LV thrombus.
- Patients with previous anterior myocardial infarction or LAD revascularization procedures
- Patients with cardiogenic shock
- Patients with LV thrombus
- Patients with advanced CKD (Cr \> 2 and those on hemodialysis)
- Recent ICH or major bleed requiring transfusion, low platelet counts \<100,000
- History of recent CVA ( within past three months)
- Patients with atrial fibrillation or other indications for chronic anticoagulation
- Pregnant patients and those with hematological disorders
The study team makes the final eligibility decision.
Where it's taking place
- Karachi, Sindh, Pakistan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Karachi, Sindh, Pakistan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.